COVID-19

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | Predicting infectious SARS-CoV-2 from diagnostic samples | Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

Developing Covid-19 Vaccines at Pandemic Speed | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial | Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 | Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | Preventing a Parallel Pandemic — A National Strategy to Protect Clinicians’ Well-Being | Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis | Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State | Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young | Hyperinflammatory shock in children during COVID-19 pandemic | Interpreting Diagnostic Tests for SARS-CoV-2 | The Ecology of Being Human by Dickson Despommier

By Dickson Despommier —
Since their establishment some 11,000 years ago, as of 2020, cities with populations greater than one hundred thousand have evolved and grown to accommodate some 60% of us (that’s 4.4 billion individuals). The trend is clear. In another 50 years it is estimated that over 80% of the human population will live in cities.

ACE inhibitors and ARBS not linked to COVID-19 infection or severity | Effective treatment of severe COVID-19 patients with tocilizumab | Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy

Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease | Adaptive COVID-19 Treatment Trial “ACTT” (NIAID) | SIMPLE I Trial results (Gilead) | Remdesivir in Chinese adults with severe COVID-19

Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 | Human leukocyte antigen susceptibility map for SARS-CoV-2